A PILOT STUDY OF THERAPY WITH PIOGLITAZONE PRIOR TO HCV TREATMENT IN HIV-1 AN

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 A5239是一项单臂两步试验性研究，在该研究中，先前对聚乙二醇干扰素(PEG-干扰素)和利巴韦林(RBV)治疗无效的已证实存在胰岛素抵抗的患者，在开始丙型肝炎再治疗之前，先用吡格列酮进行治疗。受试者将接受24至28周的吡格列酮治疗，然后继续使用聚乙二醇-干扰素/RBV进行长达48周的吡格列酮治疗。受试者将在丙型肝炎病毒(丙型肝炎病毒)和艾滋病毒治疗完成24周后接受评估，以评估持续病毒学应答(SVR)。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A5239 is a single-arm, 2-step pilot study in which prior nonresponders to peginterferon (PEG-IFN) and ribavirin (RBV) therapy, with documented insulin resistance, are treated with pioglitazone prior to instituting hepatitis C retreatment. Subjects will receive 24 to 28 weeks of pioglitazone followed by continued pioglitazone therapy with PEG-IFN/RBV for up to an additional 48 weeks. Subjects will be evaluated 24 weeks after completion of hepatitis C virus (HCV) and HIV treatment to assess for sustained virologic response (SVR).